Zobrazeno 1 - 10 of 64 pro vyhledávání: '"I. Darmon"'
1
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
2
Abstract P4-12-05: A retrospective study of 27 patients with ER-positive, HER2 negative metastatic breast cancer treated with concomitant palbociclib and radiation therapy
Autor: Youlia M. Kirova, Joelle Otz, François Clément Bidar, Hamid Mammar, K.I. Cao, Alain Fourquet, A. Labib, M. Minsat, Baptiste Porte, Alexandre Arsene-Henry, Paul Cottu, Nathaniel Scher, A. Beddok, I. Darmon, Phlip Poortmans, L. Bazire
Publikováno v: Cancer Research. 80:P4-12
Background: Palbociclib, a small-molecule inhibitor of cyclin-dependent kinases (CDK4 and CDK6), combined with letrozole increases progression-free survival among patients with previously untreated ER-positive, HER2 negative advanced breast cancer. H
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5a29ee1c6303b19602d89c01d0e66bcd
https://doi.org/10.1158/1538-7445.sabcs19-p4-12-05
Zobrazit plný text záznamu
3
Radiosurgery and stereotactic irradiation of multiple and contiguous brain metastases: A practical proposal of dose prescription methods and a literature review
Autor: A. Di Rito, Juliette Thariat, I. Troussier, I. Darmon, A. Chaikh
Publikováno v: Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique. 25(1)
Purpose In literature, there are no guidelines on how to prescribe dose in the case of radiosurgery (SRS) or stereotactic irradiation of multiple and adjacent BM. Aim of this work is to furnish practical proposals of dosimetric methods for multiple n
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7fff8d2729b37ba335ad671535324815
https://pubmed.ncbi.nlm.nih.gov/33390318
Zobrazit plný text záznamu
4
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
5
Safety and efficacy of fiducial marker implantation for robotic stereotactic body radiation therapy with fiducial tracking
Autor: Jean-Michel Vannetzel, Denis Foster, Marc Bollet, A. Toledano, Imane Khemiri, Rie von Eyben, I. Darmon, Gauthier Bouilhol, Noura Sellami, Aurelie Vouillaume, Luc Rotenberg, Remi Tannouri, Hanah Lamallem, Nathaniel Scher, Olivier Bauduceau
Publikováno v: Radiation Oncology (London, England)
Radiation Oncology, Vol 14, Iss 1, Pp 1-8 (2019)
Purpose The purpose of this study was to assess the feasibility, efficacy and toxicity of fiducial marker implantation and tracking in CyberKnife® stereotactic radiation therapy (SBRT) applied to extracranial locations. Materials and method This is
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::044c32c135b42b0da35daa07e858c915
https://pubmed.ncbi.nlm.nih.gov/31519194
Zobrazit plný text záznamu
8
Place de l’arcthérapie modulée et de la chimiothérapie concomitante dans la prise en charge des cancers du canal anal localement évolués
Autor: Pascal Fenoglietto, Catherine Dejean, C. Benahim, S. Servagi-Vernat, S. Vieillot, I. Troussier, Florence Huguet, René-Jean Bensadoun, Cécile Ortholan, Juliette Thariat, I. Darmon, L. Krebs, J. Khalifa
Publikováno v: Cancer/Radiothérapie. 19:127-138
Resume Le traitement de reference des carcinomes epidermoides du canal anal localement evolues (stades II et III) est la chimioradiotherapie exclusive. Celle-ci delivre une dose de 45 Gy a raison de cinq fractions de 1,8 Gy par semaine dans un volume
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5134e2aa93eb099b00753d5e1c3c6915
https://doi.org/10.1016/j.canrad.2014.12.005
Zobrazit plný text záznamu
9
[Technical aspects and indications of extracranial stereotactic radiotherapy]
Autor: L, Bazire, I, Darmon, V, Calugaru, É, Costa, J-L, Dumas, Y M, Kirova
Publikováno v: Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique. 22(5)
Extracranial stereotactic radiotherapy has developed considerably in recent years and is now an important part of the therapeutic alternatives to be offered to patients with cancer. It offers opportunities that have progressively led physicians to re
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::dff64c12899a4ec2b683d4f5a31f8e6a
https://pubmed.ncbi.nlm.nih.gov/30064828
Zobrazit plný text záznamu
10
Temozolomide and Bevacizumab Induction before Chemoradiotherapy in Patients with Bulky Glioblastoma and/or with Severe Neurological Impairment
Autor: Christine Desenclos, M C Morisse, Taillandier L, S. Trudel, Le Rhun E, Roufai Db, Blanchard N, Bruno Chauffert, Coutte A, Mathieu Boone, Faivre Jc, Blonski M, I. Darmon
Publikováno v: American Journal of Cancer
American Journal of Cancer, Adis, 2017, 8 (8), pp.1417-1424. ⟨10.7150/jca.18339⟩
American Journal of Cancer, 2017, 8 (8), pp.1417-1424. ⟨10.7150/jca.18339⟩
Journal of Cancer
International audience; Background. New approaches are needed for patients newly diagnosed with bulky glioblastoma (GB) and/or with severe neurological impairment that cannot benefit from first line temozolomide (TMZ)-based chemoradiotherapy. Bevaciz
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f54110ac4daa04c6ca52cf5b9c57dead
https://www.hal.inserm.fr/inserm-02940575/file/v08p1417.pdf
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje